Telabid5 mg+1 mg

Telabid is a fixed-dose combination of an anticholinergic/antispasmodic (isopropamide) and a low-dose phenothiazine (trifluoperazine), historically indicated for:

Established/traditional use

• Symptomatic relief of functional gastrointestinal disorders associated with smooth-muscle spasm and hypermotility, such as irritable bowel syndrome-type symptoms and spasm associated with peptic ulcer disease, particularly when accompanied by associated anxiety or nervous tension.

Adjunct use

• As an adjunct for the mild anxiolytic and antiemetic effect of low-dose trifluoperazine in patients whose gastrointestinal symptoms have a significant anxiety or nausea component, alongside standard management of the underlying GI condition.

Telabid is an older combination product; its use has declined as more selective antispasmodics, proton pump inhibitors, and anxiolytics with more favorable safety profiles are now generally preferred, and prescribing should follow current local clinical judgment and guidelines.

Isopropamide + Trifluoperazine is available as an oral tablet combining:

• Isopropamide (as isopropamide iodide) - an anticholinergic/antispasmodic
• Trifluoperazine (as trifluoperazine hydrochloride) - a phenothiazine, used at a low dose in this combination

Exact strengths of each component vary by manufacturer and formulation; always check the product label of the dispensed pack for the specific composition.

Telabid combines a long-acting quaternary ammonium anticholinergic (isopropamide) with a low-dose phenothiazine (trifluoperazine) in a single oral tablet. Isopropamide reduces gastrointestinal smooth-muscle spasm, motility, and glandular secretions, while low-dose trifluoperazine contributes a mild anxiolytic and antiemetic effect. Telabid was historically formulated for patients with functional gastrointestinal complaints (such as irritable bowel syndrome-type symptoms or peptic ulcer-associated spasm) who also had a significant anxiety or nervous component to their symptoms.

Telabid is an older combination and is used less commonly today, as newer, more selective agents are generally preferred; when prescribed, it should be used at the lowest effective dose for the shortest necessary duration.

Telabid belongs to the therapeutic class of gastrointestinal antispasmodic-anticholinergic and phenothiazine (antipsychotic/antiemetic) combinations, used for functional GI disorders with an associated anxiety component.

Isopropamide is a synthetic quaternary ammonium anticholinergic that competitively blocks acetylcholine at muscarinic receptors in the gastrointestinal tract, reducing smooth-muscle motility and spasm and decreasing gastric and other secretions. Its quaternary structure limits central nervous system penetration and produces a relatively long duration of peripheral anticholinergic action.

Trifluoperazine is a piperazine-phenothiazine that blocks dopamine D2 receptors (mesolimbic pathway and chemoreceptor trigger zone), producing antiemetic and, at low doses, mild anxiolytic/sedative effects; at the low doses used in Isopropamide + Trifluoperazine, its antipsychotic effect is not the intended therapeutic action, but dopamine-blocking adverse effects (including extrapyramidal symptoms) remain possible.

Together in Isopropamide + Trifluoperazine, these actions are intended to relieve gastrointestinal spasm/hypermotility while addressing coexisting anxiety and nausea.

Telabid is taken orally, usually two to three times daily. Swallow the tablet whole with a glass of water; it may be taken with or without food. Take doses of Telabid at evenly spaced intervals as directed by the physician, and continue for the duration prescribed. Do not crush or chew unless the product labeling specifically permits it.

Telabid has clinically significant interactions related to both its anticholinergic (isopropamide) and phenothiazine (trifluoperazine) components:

• Other anticholinergic drugs (e.g., tricyclic antidepressants, first-generation antihistamines, other antispasmodics): Concurrent use with Telabid increases the risk of additive anticholinergic effects such as severe dry mouth, urinary retention, constipation, blurred vision, and confusion, particularly in elderly patients.
• CNS depressants (alcohol, benzodiazepines, opioids, sedative-hypnotics): Concurrent use with Telabid can produce additive sedation and CNS/respiratory depression.
• Other dopamine-blocking or QT-prolonging drugs (e.g., other antipsychotics, certain antiarrhythmics, some macrolide antibiotics): Concurrent use with Telabid may increase the risk of extrapyramidal symptoms and QT-interval prolongation/arrhythmia.
• Antacids and adsorbents (e.g., aluminum/magnesium-containing antacids): May reduce absorption of the trifluoperazine component of Telabid; separate dosing times where possible.
• Drugs that lower seizure threshold: Trifluoperazine can lower the seizure threshold, so caution is needed when Telabid is combined with other agents that share this effect.

Side effects of Telabid reflect both its anticholinergic (isopropamide) and phenothiazine (trifluoperazine) components.

Common

• Dry mouth, blurred vision, constipation
• Drowsiness/sedation
• Dizziness

Less common

• Urinary hesitancy, palpitations
• Photosensitivity, skin rash
• Orthostatic hypotension

Rare but serious

• Extrapyramidal symptoms (dystonia, akathisia, parkinsonism) and, with prolonged use, tardive dyskinesia, related to the trifluoperazine component
• Neuroleptic malignant syndrome
• QT-interval prolongation and arrhythmia
• Blood dyscrasias (e.g., leukopenia, agranulocytosis)
• Cholestatic jaundice

Pregnancy: There are no adequate, well-controlled studies of Telabid in pregnant women. Phenothiazines such as trifluoperazine have been associated in some reports with extrapyramidal effects in neonates exposed late in pregnancy. Telabid should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: Trifluoperazine and anticholinergic agents are excreted in breast milk in small amounts and may affect a nursing infant (sedation, anticholinergic effects, reduced milk supply from anticholinergic action). Telabid should be used during breastfeeding only under medical advice, weighing benefit against potential risk to the infant.

Anticholinergic effects

Telabid can cause dry mouth, blurred vision, constipation, and urinary hesitancy; use with caution in patients with prostatic hypertrophy or pre-existing constipation, and avoid in narrow-angle glaucoma (see Contraindications).

Extrapyramidal symptoms and tardive dyskinesia

The trifluoperazine component of Telabid can cause extrapyramidal symptoms, and prolonged use may result in tardive dyskinesia, which may be irreversible; use the lowest effective dose for the shortest duration and monitor for early signs of abnormal movements.

Sedation and CNS effects

Telabid may impair mental alertness and physical coordination; caution patients about driving or operating machinery until they know how it affects them, and use caution with concurrent CNS depressants.

QT prolongation

Trifluoperazine can prolong the QT interval; use Telabid with caution in patients with cardiac disease, electrolyte disturbances, or concurrent use of other QT-prolonging drugs.

Heat exposure

Telabid can impair the body's ability to reduce core temperature (via anticholinergic reduction in sweating); use caution in hot weather or with strenuous activity.

Elderly patients

Elderly patients are more sensitive to both the anticholinergic and phenothiazine effects of Telabid, including confusion, hypotension, and increased fall risk; see Use in Special Populations.

Do not stop abruptly after prolonged use

After prolonged use, Telabid should not be stopped abruptly; discontinue gradually under medical supervision to reduce the risk of withdrawal-related symptoms.

Overdose of Telabid can produce an exaggeration of anticholinergic effects (severe dry mouth, blurred vision, urinary retention, tachycardia, hyperthermia, agitation, confusion) combined with phenothiazine toxicity (severe sedation, hypotension, extrapyramidal reactions, arrhythmia, and QT prolongation); severe cases may progress to seizures, coma, or cardiorespiratory depression.

Overdose of Telabid is a medical emergency. Seek immediate medical attention or contact emergency services/a poison control center. Treatment is supportive and symptomatic (e.g., airway management, cardiac monitoring); do not attempt to induce vomiting or give any specific home treatment without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric patients

Safety and efficacy of Telabid have not been established in children; its use is generally not recommended in this age group.

Elderly patients

Elderly patients are more susceptible to the anticholinergic effects (confusion, urinary retention, constipation) and to the sedative, hypotensive, and extrapyramidal effects of the trifluoperazine component of Telabid; start at the lowest effective dose, if used at all, and monitor closely.

Hepatic impairment

Use Telabid with caution, as trifluoperazine is hepatically metabolized; reduced clearance may increase the risk of adverse effects.

Renal impairment

No well-established dose adjustment exists for Telabid; use with caution and monitor for anticholinergic and phenothiazine-related adverse effects.

Parkinson's disease

Avoid Telabid in patients with Parkinson's disease, as the dopamine-blocking effect of trifluoperazine can worsen parkinsonian symptoms.

Telabid is generally used for the shortest duration needed to control symptoms of the underlying functional GI disorder and associated anxiety, with periodic reassessment by the physician. Because prolonged use of the trifluoperazine component carries a risk of tardive dyskinesia, continuous long-term use of Telabid is discouraged, and continued need should be reviewed regularly.

Anticholinergic/antispasmodic (isopropamide) combined with a piperazine-phenothiazine antipsychotic/antiemetic (trifluoperazine)

Isopropamide, a quaternary ammonium anticholinergic, competitively antagonizes acetylcholine at muscarinic receptors in gastrointestinal smooth muscle and glands, reducing motility, spasm, and secretions. Trifluoperazine, a phenothiazine, blocks dopamine D2 receptors in the chemoreceptor trigger zone and mesolimbic pathways, producing antiemetic effects and, at the low dose used in Isopropamide + Trifluoperazine, mild anxiolytic/sedative effects. The combined action of Isopropamide + Trifluoperazine is intended to relieve gastrointestinal spasm while addressing associated nausea and anxiety.

Safety and efficacy of Telabid have not been established in pediatric patients, and it is not generally recommended for use in children. If a physician determines that Telabid is necessary in an older child or adolescent, it should be used with close monitoring for anticholinergic effects and extrapyramidal reactions, at the lowest effective dose.